A Phase II open-label, Multicenter study of Apalutamide, Abiraterone Acetate and Prednisone in African American and Caucasian men with metastatic castrate-resistant prostate cancer

Administered By

Awarded By

Contributors

Start/End

  • May 11, 2017 - April 30, 2022